Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 12, 2012. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding their interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of insider share transactions and does not contain financial performance data.
Material Changes
The material change reported is the acquisition of Ordinary Shares by specific company insiders on November 9, 2012, executed through the Company's ShareReward Plan at a price of 1369 pence per share. The transactions involved both personal contributions and matching company contributions.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Transaction Date: November 9, 2012.
- Share Price: 1369 pence per Ordinary Share.
- Participants: Sir Andrew Witty, Mr S Dingemans, Mr S M Bicknell, Mr R G Connor, Mr D S Redfern, Ms C Thomas, Mr P C Thomson, Dr P J T Vallance, Ms E Walmsley, and Mrs V A Whyte.
- Transaction Structure: Each participant acquired shares under both the personal contribution element and the matching element (Company contribution) of the ShareReward Plan.
- Volume: Most participants acquired 9 shares per element; Mr P C Thomson acquired 8 shares per element; Dr P J T Vallance acquired 10 shares per element.